[Federal Register Volume 68, Number 73 (Wednesday, April 16, 2003)]
[Notices]
[Pages 18658-18659]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-9285]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: (301) 496-7057; fax: (301) 402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Scytovirins and Related Conjugates, Antibodies, Compositions, Nucleic 
Acids, Vectors, Host Cells, Methods of Production and Methods of Using 
Scytovirin

Michael R. Boyd (NCI), Barry R. O'Keefe (NCI), Tawnya C. McKee (NCI), 
Heidi R. Bokesch (SAIC).
Serial No. 60/381,322 filed 16 May 2002,
Licensing Contact: Sally Hu; (301) 435-5606; [email protected].
    This invention provides: (1) Isolated and purified antiviral 
peptides or antiviral proteins named Scytovirins isolated and purified 
from aqueous extracts containing the cyanobacteria, Scytonema varium; 
(2) an antibody which binds an epitope of Scytovirin isolated and 
purified from Scytonema

[[Page 18659]]

varium; (3) a purified nucleic acid molecule that comprises a sequence 
which encodes an amino acid sequence homologous to Scytovirin; (4) a 
vector comprising the isolated and purified nucleic acid molecule and a 
host cell or organism comprising the vector; (5) a conjugate comprising 
the peptide and an effector component; and (6) a method of inhibiting 
prophylactically and therapeutically a viral infection. Thus, this 
invention may represent potential new therapeutics for treatment of 
retroviral infections, including AIDS. This invention is further 
described in Bokesch et al., ``A Potent Anti-HIV Protein from the 
Cultured Cyanobacteria Scytonema varium,'' Biochemistry, 2003, 42, 
2578-2584.

Benzoylalkylindolepyridinium Compounds and Pharmaceutical Compositions 
Comprising Such Compounds

William G. Rice, Mingjun Huang, Robert W. Buckheit, Jr., David G. 
Covell, Grzegorz Czerwinski, Christopher Michejda, and Vadim Makarov 
(NCI).
DHHS Reference No. E-278-98/1 filed 18 Dec 2000 (PCT/US01/48311).
Licensing Contact: Sally Hu; (301) 435-5606; e-mail: [email protected].

    The present invention provides novel antiviral compounds active 
against HIV. These compounds, referred to as 
benzoylalkylindolepyridinium compounds (BAIPs) are effective against 
HIV isolates that have developed mutations rendering conventional drugs 
ineffective. BAIPs apparently do not require intracellular 
phosphorylation nor bind to the reverse transcriptase (RT) active site, 
which distinguishes their mechanism of action from the 
dideoxynucleoside (ddN) and acyclic nucleoside phosphonate (ANP) 
nucleoside analog drugs. ddN and ANP have proven clinically effective 
against limited human immunodeficiency virus (HIV) infection, but 
resistance rapidly emerges due to mutations in and around the RT active 
site. The BAIPs also may be distinguished from non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), in part because the BAIPs bind to a 
different site on the RT enzyme. The usage of NNRTIs is limited by the 
rapid emergence of resistant strains also. Moreover, unlike the NNRTIs, 
BAIPs of the present invention have been shown to be effective against 
HIV-1, HIV-2 and simian immunodeficiency virus (SIV) proliferation. 
Thus, BAIPs are broadly antiviral, non-nucleoside reverse transcriptase 
inhibitors (BANNRTIs).

Spontaneous Breathing Apparatus and Method

Theodor Kolobow (NHLBI).
Serial No. 08/933,003 filed 18 Sep 1997; PCT/US98/19714 filed 18 Sep 
1998; Serial No. 09/555,229 filed 26 May 2000.
Licensing Contact: Michael Shmilovich; 301/435-5019; email: 
[email protected].
    A novel assisted breathing system and method that greatly 
decreases/eliminates the work of breathing and is under the total 
control of the patient.
    The system includes a minitracheostomy tube, a reverse thrust gas 
insufflation catheter introduced through a special minitracheostomy 
tube to deliver well humidified air/oxygen to near the carina, and a 
threshold valve to limit airway plateau pressure. Inspiration is 
effected through spontaneous closing of the glottic opening, while 
expiration follows opening of the glottis. The patient can control the 
rate of respiration and tidal volumes. Lung inflation is therefore 
passive and accounts for the nominal work of breathing. Speech, sound, 
and coughing ability remains unimpeded.

Ultrasound-Hall Effect Imaging System And Method

Han Wen (NHLBI).
Serial No. 60/021,204 filed 03 Jul 1996; PCT/US97/11272 filed 02 Jul 
1997; Serial No. 09/202,459 filed 14 Dec 1998; and related foreign 
patent applications.
Licensing Contact: Michael Shmilovich; (301) 435-5019; email: 
[email protected].

    The invention provides for a novel ultrasound-based imaging 
modality that is based on the interaction of a static magnetic field 
and conductive moieties in the imaged sample under electrical 
excitation. The invention also provides a novel ultrasound-based 
imaging modality that provides a contrast mechanism which reflects the 
conductivity distribution of the medium being imaged. The disclosed 
methods and system have the following advantages over other ultrasonic 
imaging systems: (a) The method is not limited to contrast based solely 
on acoustic properties; (b) it dispenses with acoustic beam excitation 
and is suitable for fast 2D and 3D image formation with wide angle 
signal reception. A working prototype system has been constructed and 
demonstrated 3D imaging. Results are published in peer reviewed 
journals: H. Wen, Ultrason. Imaging 2000 Apr;22(2):123-136; H. Wen, 
Ultrason. Imaging 1999 Jul;21(3):186-200; H. Wen et al., Ultrason. 
Imaging 1998 Jul;20(3):206-220; H. Wen et al., IEEE TransBiomed. Eng. 
1998 Jan;45(1):119-124.

    Dated: April 8, 2003.
Steven M. Ferguson,
Acting Director, Division of Technology Development and Transfer, 
Office of Technology Transfer, National Institutes of Health.
[FR Doc. 03-9285 Filed 4-15-03; 8:45 am]
BILLING CODE 4140-01-P